Levodopa CAS 59-92-7

180570

Synonyms: (-)-Dopa, (S)-3,4-Dihydroxyphenylalanine, 3-Hydroxytyrosine, L-DOPA, Alphadopa, Bendopa, Brocadopa, Cidandopa, Deadopa, Dopaflex, Dopaidan, Dopal, Dopalina, Dopar, Doparkine, Doparl, Dopasol, Dopaston, Dopastral, Dopicar, Doprin, Eldopal, Eldopar, Laradopa, Maipedopa, Parda, Pardopa, Syndopa, Veldopa, Weldopa

250 g € 180
500 g € 260
1 kg € 350
2 kg € 570
For bulk quantities contact us at [email protected]
Cat. No. NST-10-208
CAS 59-92-7
Purity 98% (HPLC)
Appearance White powder
Molecular formula C9H11NO4
Molecular weight 197,19
Storage +2 … +8 °C

Certificate of analysis available by request to [email protected]

SKU: N/A Categories: ,
Description

Levodopa: Essential Precursor in Parkinson’s Disease Research

1. Molecular Identity

  • Chemical Name: (S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
  • CAS Number: 59-92-7
  • Source: Synthetic amino acid, also found naturally in certain plants

2. Biochemical Significance

Levodopa (L-DOPA) is the immediate precursor of dopamine, a crucial neurotransmitter in the central nervous system. Its ability to cross the blood-brain barrier and convert to dopamine makes it a cornerstone in neuropharmacological research, especially in studies related to Parkinson’s disease and motor function disorders.

3. Key Research Properties

  • Dopamine Precursor: Increases central dopamine levels
  • Model Compound: Widely used in Parkinson’s disease models
  • Blood-Brain Barrier Penetration: Efficient CNS availability
  • Neurotransmitter Modulation: Impacts dopaminergic signaling pathways

4. Potential Research Applications

  • Optimization of Parkinson’s treatment strategies
  • Neurodegenerative disease modeling
  • Studies of dopaminergic neurotransmission
  • Investigations in movement and motor control disorders

5. Current Research Focus

Ongoing studies are exploring Levodopa’s role in:

  • Long-term efficacy and tolerance mechanisms
  • Combination strategies to enhance CNS effects
  • Formulation and CNS-targeted delivery development
  • Applications in other neurological conditions

6. Formulation Challenges and Innovations

Researchers are actively developing:

  • Extended-release and controlled-release systems
  • Formulations minimizing peripheral conversion and side effects
  • Targeted CNS delivery platforms

7. Regulatory Considerations

Levodopa (CAS 59-92-7) is used in pharmaceutical formulations approved for Parkinson’s disease. Its application in research should follow appropriate regulatory and ethical guidelines for laboratory and preclinical use.

8. Future Research Directions

Anticipated areas of exploration include:

  • Neuroprotective potential in early-stage neurodegeneration
  • Personalized dosing strategies based on patient profiles
  • Innovative delivery methods for enhanced CNS selectivity

9. Collaborative Opportunities

We welcome inquiries from neuroscientists, pharmaceutical research teams, and academic institutions interested in Levodopa for their R&D needs. For technical specifications, samples, or partnership opportunities, contact us at [email protected].

Join us in supporting advanced neurological research with Levodopa – a key compound in the study of dopamine metabolism and CNS function.